Panagora Asset Management Inc. Has $22.44 Million Stake in Travere Therapeutics, Inc. $TVTX

Posted by Brenda Bartman on Jun 16th, 2026

Panagora Asset Management Inc. lifted its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 3.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 587,354 shares of the company’s stock after buying an additional 17,659 shares during the period. Panagora Asset Management Inc.’s holdings in Travere Therapeutics were worth $22,443,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Mariner LLC grew its position in shares of Travere Therapeutics by 105.6% during the 4th quarter. Mariner LLC now owns 18,219 shares of the company’s stock worth $696,000 after buying an additional 9,359 shares during the period. Entropy Technologies LP grew its position in shares of Travere Therapeutics by 32.2% during the 4th quarter. Entropy Technologies LP now owns 22,201 shares of the company’s stock worth $848,000 after buying an additional 5,408 shares during the period. Aigen Investment Management LP acquired a new stake in shares of Travere Therapeutics during the 4th quarter worth approximately $427,000. FORA Capital LLC acquired a new stake in shares of Travere Therapeutics during the 4th quarter worth approximately $307,000. Finally, Segall Bryant & Hamill LLC acquired a new stake in shares of Travere Therapeutics during the 4th quarter worth approximately $1,039,000.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, insider Jula Inrig sold 20,000 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $45.00, for a total transaction of $900,000.00. Following the transaction, the insider directly owned 111,473 shares in the company, valued at approximately $5,016,285. This trade represents a 15.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Elizabeth E. Reed sold 44,715 shares of the firm’s stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $41.21, for a total value of $1,842,705.15. Following the transaction, the insider owned 111,996 shares in the company, valued at approximately $4,615,355.16. This trade represents a 28.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 390,015 shares of company stock worth $15,614,528. 4.44% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. TD Cowen raised their price objective on shares of Travere Therapeutics from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Wall Street Zen downgraded shares of Travere Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Citigroup raised their price objective on shares of Travere Therapeutics from $62.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday. Wells Fargo & Company raised their price objective on shares of Travere Therapeutics from $50.00 to $65.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Weiss Ratings raised shares of Travere Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, May 21st. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $50.83.

Check Out Our Latest Analysis on Travere Therapeutics

Travere Therapeutics Price Performance

Shares of NASDAQ:TVTX opened at $53.80 on Tuesday. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 3.16. The stock’s fifty day simple moving average is $42.17 and its two-hundred day simple moving average is $35.38. Travere Therapeutics, Inc. has a 1-year low of $13.88 and a 1-year high of $53.88. The stock has a market cap of $5.00 billion, a PE ratio of -233.90 and a beta of 1.13.

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last issued its quarterly earnings data on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The business had revenue of $127.20 million for the quarter, compared to analysts’ expectations of $136.23 million. During the same period last year, the business earned ($0.47) EPS. The business’s revenue was up 55.6% on a year-over-year basis. As a group, analysts forecast that Travere Therapeutics, Inc. will post -0.29 EPS for the current fiscal year.

About Travere Therapeutics

(Free Report)

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.